The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Diabetic macular edema remains an important cause of vision ... techniques. The Diabetic Retinopathy Clinical Research (DRCR) Network, which includes over 199 participating sites, is currently ...

Diabetic macular edema can result in low vision or vision loss. Early treatment can help preserve vision longer. Diabetic macular edema (DME) is a complication of diabetes. Over time, high blood ...

especially diabetic macular edema, and due to proliferative diabetic retinopathy. Vision loss due to DR is preventable with the appropriate monitoring and timely treatment. Improved patient and ...

Diabetes can lead to eye problems, and a common one is diabetic macular edema (DME), causing vision ... in retinal disease beyond diabetic retinopathy." With 93 million people globally affected ...

“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding th ...

Jefferies said it sees a “major turnaround in place for 2025,” with such upcoming catalysts as Phase 1b data for its drug KSI-101 in the treatment of macular edema secondary to inflammation ...

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum ... as the first topical eye drop to treat DME ZUG, Switzerland, Oct. 21, ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

OCT angiography can measure changes in the foveal avascular zone (FAZ) area. FAZ area deteriorated in stable eyes with proliferative diabetic retinopathy and macular capillary nonperfusion.